Statin treatment and gene expression of anti-atherogenic factor C-type natriuretic peptide system in stenotic aortic valves

Journal of Heart Valve Disease

Volumn 20, Issue 5, 2011, Pages 545-551

  Peltonen, Tuomas ^a   Ohtonen, Pasi ^b   Nap̈änkangas, Juha ^a   Ohukainen, Pauli ^a   Ruskoaho, Heikki ^a   Taskinen, Panu ^b  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; MESSENGER RNA; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE TYPE C; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ATRIAL NATRIURETIC FACTOR RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; AORTA VALVE REGURGITATION; AORTA VALVE STENOSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; AORTA VALVE; BIOSYNTHESIS; CALCINOSIS; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, C-TYPE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RNA, MESSENGER;

EID: 84855367842     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997;95:2262-2270
2. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005;111:3316-3326
3. Aronow WS. Valvular aortic stenosis in the elderly. Cardiol Rev 2007;15:217-225
4. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994;90:844-853
5. O'Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995;92:2163-2168
6. Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004;44:1859-1866
7. Peltonen T, Napankangas J, Vuolteenaho O, et al. Apelin and its receptor APJ in human aortic valve stenosis. J Heart Valve Dis 2009;18:644-652
8. Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003;107:2181-2184
9. Pohjolainen V, Taskinen P, Soini Y, et al. Noncollagenous bone matrix proteins as a part of calcific aortic valve disease regulation. Hum Pathol 2008;39:1695-1701
10. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, for the ASTRONOMER Investigators. Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis. Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial. Circulation 2010;121:306-314
11. Cowell SJ, Newby DE, Prescott RJ, et al., Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-2397
12. Rosenhek R, Baumgartner H. Aortic sclerosis, aortic stenosis and lipid-lowering therapy. Expert Rev Cardiovasc Ther 2008;6:385-390
13. Rossebo AB, Pedersen TR, Boman K, et al. the SEAS Investigators. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. N Engl J Med 2008;359:1343-1356
14. Dichtl W, Alber HF, Feuchtner GM, et al. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). Am J Cardiol 2008;102:743-748
15. Clearfield M. Rosuvastatin in older patients with systolic heart failure. Curr Atheroscler Rep 2009;11:5-6
16. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239
17. Sadek MM, Haddad T, Haddad H. The role of statins in chronic heart failure. Curr Opin Cardiol 2009;24:167-171
18. Peltonen TO, Taskinen P, Soini Y, et al. Distinct downregulation of C-type natriuretic peptide system in human aortic valve stenosis. Circulation 2007;116:1283-1289
19. Ahluwalia A, MacAllister RJ, Hobbs AJ. Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res Cardiol 2004;99:83-89
20. Scotland RS, Ahluwalia A, Hobbs AJ. C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther 2005;105:85-93
21. Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, et al. Amino-terminal pro-C-type natriuretic peptide is associated with arterial stiffness, endothelial function and early atherosclerosis. Atherosclerosis 2010;211:649-655
22. Qian JY, Haruno A, Asada Y, et al. Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ Res 2002;91:1063-1069
23. Ahluwalia A, Hobbs AJ. Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor. Trends Pharmacol Sci 2005;26:162-167
24. Scotland RS, Cohen M, Foster P, et al. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci USA 2005;102:14452-14457
25. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001;88:693-695
26. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001;104:2205-2209
27. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002;40:1723-1730
28. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110:1291-1295
29. Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkila J, Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994;15:865-870
30. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-634
31. Antonini-Canterin F, Hirsu M, Popescu BA, et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008;102:738-742
32. Naruko T, Itoh A, Haze K, et al. C-Type natriuretic peptide and natriuretic peptide receptors are expressed by smooth muscle cells in the neointima after percutaneous coronary intervention. Atherosclerosis 2005;181:241-250
33. Holme I, Boman K, Brudi P, et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am J Cardiol 2010;105:1802-1808
34. Gilmanov D, Bevilacqua S, Mazzone A, Glauber M. Do statins slow the process of calcification of aortic tissue valves? Interact Cardiovasc Thorac Surg 2010;11:297-301
35. Rajamannan NM. Mechanisms of aortic valve calcification: the LDL-density-radius theory: a translation from cell signaling to physiology. Am J Physiol Heart Circ Physiol 2010;298:H5-15